Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib

    October 2025 in “ Journal of Clinical Medicine ”
    Daniel Muñoz‐Barba, Carmen García‐Moronta, Alberto Soto‐Moreno … Salvador Arias‐Santiago
    Studysummary This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 25

    1. Real-Life Effectiveness and Safety of Baricitinib in Adults with Alopecia Areata: A Multicenter Study Journal of the European Academy of Dermatology and Venereology · 2025
    2. Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region International Journal of Dermatology · 2025
    3. Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center The Journal of Dermatology · 2025
    4. Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study Journal of Dermatological Treatment · 2025
    5. Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study Journal of the European Academy of Dermatology and Venereology · 2024
    6. Predictors And Management Of Inadequate Response To JAK Inhibitors In Alopecia Areata American Journal of Clinical Dermatology · 2024
    7. Evaluation of Serum Inflammatory Markers and Their Relationship to Treatment Response in Alopecia Areata Patients Dermatology Practical & Conceptual · 2024
    8. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    9. Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients Acta dermato-venereologica · 2024
    10. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study Acta dermato-venereologica · 2023
    11. 67 Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the ALLEGRO Phase 2b/3 and Ongoing Phase 3 ALLEGRO-LT Studies Journal of Investigative Dermatology · 2023
    12. Treatments for Alopecia Areata: A Network Meta-Analysis The Cochrane library · 2023
    13. Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience Journal of Dermatological Treatment · 2023
    14. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data Dermatology and Therapy · 2023
    15. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    16. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023
    17. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    18. Biomarkers in Alopecia Areata: A Systematic Review and Meta-Analysis Autoimmunity reviews · 2023
    19. Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis Frontiers in immunology · 2023
    20. Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs Clinical, Cosmetic and Investigational Dermatology · 2023
    21. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    22. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    23. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata Drug Design Development and Therapy · 2022
    24. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    25. SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss Journal of The American Academy of Dermatology · 2016